Goshen Hospital

May 4th, 2015

Materials Licensing Section
U.S. Nuclear Regulatory Commission
Region III
2443 Warrenville Road, Suite 210
Lisle, Illinois 60532-4352

RE: License #13-18845-01

To whom is may concern:

This is to notify you that we have approved Nicholas Abel, M. D. as an authorized user for the materials in 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131. Dr. Abel is listed on the license for Memorial Hospital, South Bend, Ind., #13-18881-01, a copy of which is enclosed.

Please contact us or our consultant, David Close at (888) 456-5255, if you have any questions. Thank you for your attention to this matter.

Sincerely,

Mark Podgorski, PE MBA
Vice President Hospital Operations
Indiana University Health Goshen Hospital

200 High Park Ave.
PO Box 139
Goshen, IN 46527
574.533.2141

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
2443 WARRENVILLE RD. SUITE 210
LISLE, IL 60532-4352

MAR 0 4 2015

Daniel J. Archambeault, M.S.
Radiation Safety Officer
Memorial Hospital
615 North Michigan Street
South Bend, IN 46601

Dear Mr. Archambeault:

Enclosed is Amendment No. 84 renewing your NRC Material License No. 13-18881-01 in accordance with your request.

Additionally, based on your provided information we have concluded that all licensable radioactive material has been removed from your facility located at 621 Memorial Drive, Suite 502, South Bend, Indiana and residual radioactive material attributable to licensed activities does not exceed current NRC criteria. Therefore, we have authorized the release of facilities located at 621 Memorial Drive, Suite 502, South Bend, Indiana, for unrestricted use.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Statement of Policy and Procedure for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

The NRC's Safety Culture Policy Statement became effective in June 2011. While a policy statement and not a regulation, it sets forth the agency's *expectations* for individuals and organizations to establish and maintain a positive safety culture. You can access the policy statement and supporting material that may benefit your organization on NRC's safety culture Web site at http://www.nrc.gov/about-nrc/regulatory/enforcement/safety-culture.html. We strongly encourage you to review this material and adapt it to your particular needs in order to develop and maintain a positive safety culture as you engage in NRC-regulated activities.

NRC's Regulatory Issue Summary (RIS) 2005-31 provides criteria to identify security-related sensitive information and guidance for handling and marking of such documents. This ensures that potentially sensitive information is not made publicly available through ADAMS, the NRC's electronic document system. Pursuant to NRC's RIS 2005-31 and in accordance with 10 Code

**The enclosed document contains sensitive security-related information.
When separated from this cover letter this letter is uncontrolled.**

of Federal Regulations 2.390, the enclosed license document is exempt from public disclosure because its disclosure to unauthorized individuals could present a security vulnerability. The RIS may be located on the NRC Web site at: http://www.nrc.gov/reading-rm/doc-collections/gen-comm/reg-issues/2005/ri200531.pdf and the link for frequently asked questions regarding protection of security related sensitive information may be located at: http://www.nrc.gov/reading-rm/sensitive-info/faq.html.

A copy of this letter will be available electronically for public inspection in the NRC Public Document Room or from the NRC's Agencywide Documents Access and Management System (ADAMS), accessible from the NRC Web site at http://www.nrc.gov/reading-rm/adams.html.

Sincerely,

Frank P. D. Tran
Health Physicist
Materials Licensing Branch

License No. 13-18881-01
Docket No. 030-17335

Enclosure: Amendment No. 84

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 84

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Memorial Hospital 2. 615 North Michigan Street South Bend, IN 46601	In accordance with letters dated **September 11, 2014**, and **December 16, 2014**, 3. License number 13-18881-01 is renewed in its entirety to read as follows: 4. Expiration date **March 31, 2025** 5. Docket No. 030-17335 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie
D. Iridium-192 permitted by 10 CFR 35.400	D. Sealed source (Best Medical International, Inc., Model 81-01)	D. 1 curie
E. Cesium-131 permitted by 10 CFR 35.400	E. Sealed source (IsoRay Model CS-1)	E. 1 curie
F. Iodine-125 permitted by 10 CFR 35.400	F. Sealed sources (Bard Brachtherapy, Inc., Model STM 1251; Implant Sciences Corp. Model 3500 (I-plant); Best Medical International, Inc., Model 2301; Medi-Physics, Inc., Models 6711 (OncoSeed™) and 9011; and IsoAid, L.L.C., Model IAI-125A (Advantage™ I-125))	F. 1 curie

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-18881-01

Docket or Reference Number
030-17335

Amendment No. 84

G. Palladium-103 permitted by 10 CFR 35.400	G. Sealed sources (Theragenics Corporation Theraseed Model 200 and Best Medical International, Inc., Model 2335)	G. 1 curie
H. Iridium-192 permitted by 10 CFR 35.600	H. Sealed source (Varian Medical Systems Haan GmbH Model GammaMed 232)	H. Two sources, not to exceed 12 curies per source and 20 curies total
I. Yttrium-90 permitted by 10 CFR 35.1000	I. Sealed source (Sirtex Medical Limited SIR-Spheres microspheres manufactured by Sirtex Wilmington LLC, Sirtex Medical Limited or ANSTO Radiopharmaceuticals and Industrials)	I. 1 curie

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. through G. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

H. One source for medical use, as permitted by 10 CFR 35.600, in a GammaMed Plus High Dose Rate (HDR) remote afterloading brachytherapy device. The source activity may not exceed 10 curies at the time of installation. One source (not to exceed 12 curies while stored pending installation) in a shipping container for source replacement.

I. For permanent manual brachytherapy using Sirtex Wilmington LLC SIR-Spheres delivery system permitted by 10 CFR 35.1000.

CONDITIONS

10. A. Licensed material may be used or stored at the licensee's facilities located at 615 N. Michigan Street, South Bend, Indiana.

B. Licensed material listed in Subitems 6.A. and 6.B. (excluding PET imaging) may be used at the licensee's facility located at 610 North Michigan Street, Suite 400, South Bend, Indiana.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-18881-01

Docket or Reference Number
030-17335

Amendment No. 84

C. Licensed material listed in Subitem 6.B. may be used at the licensee's facility located at 301 E. Day Road, Mishawaka, Indiana.

11. The Radiation Safety Officer is Daniel J. Archambeault, M.S.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users	Material and Use
L. M. Galup, M.D.	10 CFR 35.100.
Brett B. Carmichael, M.D.	10 CFR 35.100 and 35.200.
J. A. Van Dyke, M.D.	10 CFR 35.100 and 35.200.
D. A. Boll, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.1000, limited to yttrium-90 as SIR-Spheres.
T. Seiffert, M.D.	10 CFR 35.100 and 35.200.
Mark J. Ormson, M.D.	10 CFR 35.100 and 35.200.
Karl W. Schultz, M.D.	10 CFR 35.100, 35.200 and 35.300.
Gerard Duprat, Jr., M.D.	10 CFR 35.100, 35.200 and 35.300, limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries.
Francoise Marie Dion, M.D.	10 CFR 35.100, 35.200 and 35.300.
Pedro A. Miro, M.D.	10 CFR 35.100, 35.200 and 35.300.
Alphonse H. Harding, M.D.	10 CFR 35.100, 35.200 and 35.300.
Thomas Fischback, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.1000, limited to yttrium-90 as SIR-Spheres.
Russell Brian Midkiff, M.D.	10 CFR 35.100, 35.200 and 35.300.
Alan B. Engel, M.D.	10 CFR 35.100, 35.200 and 35.300, limited to oral administration of sodium iodide I-131.
Kevin Michael Small, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding sodium iodide I-131).

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-18881-01

Docket or Reference Number
030-17335

Amendment No. 84

Authorized Users	Material and Use
Allison Marie Lamont, M.D.	10 CFR 35.100, 35.200 and 35.300.
Michael F. Grantham, M.D.	10 CFR 35.100 and 35.200.
Katrina T. Venderveen, M.D.	10 CFR 35.100 and 35.200.
Samir Bipin Patel, M.D.	10 CFR 35.100, 35.200 and 35.300.
David Charles D'Andrea, M.D.	10 CFR 35.100, 35.200 and 35.300.
Mary C. Dynes, M.D.	10 CFR 35.100, 35.200 and 35.300.
Albert Cho, M.D.	10 CFR 35.100, 35.200 and 35.300, limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries.
David A. Hornback, M.D.	10 CFR 35.300, 35.400, 35.600, limited to iridium-192 in HDR remote afterloading brachytherapy device and 35.1000, limited to yttrium-90 as SIR-Spheres.
Christine Marie O'Malley, M.D.	10 CFR 35.100 and 35.200.
Jonathan W. Weiss, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.1000, limited to yttrium-90 as SIR-Spheres.
William S. Sarnat, M.D.	10 CFR 35.200.
Sachin Patel, M.D.	10 CFR 35.200.
Vijay Arvindkumar Mehta, M.D.	10 CFR 35.200.
Charles Augustine Mathis, M.D.	10 CFR 35.200.
Shawn Kaser, M.D.	10 CFR 35.200.
John F. Kobayashi, M.D.	10 CFR 35.200.
Justin J. Lightburn, M.D.	10 CFR 35.100, 35.200 and 35.300, limited to oral administration of sodium iodide I-131.
Omar Ali, M.D.	10 CFR 35.200.
Breno Santiago da Silva Pessanha, M.D.	10 CFR 35.200.
Samuel D. McGrath, M.D.	10 CFR 35.600, limited to iridium-192 in HDR remote afterloading brachytherapy device.
Michael W. Dye, Jr., M.D.	10 CFR 35.100, 35.200 and 35.300, limited to oral administration of sodium iodide I-131.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-18881-01

Docket or Reference Number
030-17335

Amendment No. 84

Authorized Users	Material and Use
Nazar Golewale, M.D.	10 CFR 35.100 and 35.200.
Thomas K. Rhee, M.D.	10 CFR 35.100 and 35.200.
Benjamin Jon Moreno, M.D.	10 CFR 35.200 and 35.300, limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries.
Sridevi Sompalli, M.D.	10 CFR 35.100, 35.200 and 35.300, limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries.
Alexander Tawadros, M.D.	10 CFR 35.100, 35.200 and 35.300, limited to oral administration of sodium iodide I-131.
Eldon Olson, M.D.	10 CFR 35.100 and 35.200.
Nicholas Abel, M.D.	10 CFR 35.100, 35.200 and 35.300, limited to oral administration of sodium iodide I-131.

C. The following individual is an authorized medical physicist:

Authorized Medical Physicist	Material and Use
Daniel J. Archambeault, M.S.	Iridium-192 in High Dose Rate Remote Afterloading Brachytherapy device for calibration, spot checks and training.

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-18881-01

Docket or Reference Number
030-17335

Amendment No. 84

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated September 11, 2014.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAR 0 4 2015

By _____
Frank P. D. Tran
Materials Licensing Branch
Region III

Goshen Center for Cancer Care

200 High Park Ave.
PO Box 139
Goshen, IN 46527

604 605 60532S 6-181

4119150507-195652

4

PRSRT FIRST-CLASS MAIL
US POSTAGE PAID
South Bend, IN
PERMIT# 498

TEMP-RETURN SERVICE REQUESTED

60532

RECEIVED MAY 13 2015

Materials Licensing Section
U.S. Nuclear Regulatory Commission
Region III
2443 Warrenville Road, Suite 210
Lisle, Illinois 60532-4352